JP2021501150A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021501150A5 JP2021501150A5 JP2020523323A JP2020523323A JP2021501150A5 JP 2021501150 A5 JP2021501150 A5 JP 2021501150A5 JP 2020523323 A JP2020523323 A JP 2020523323A JP 2020523323 A JP2020523323 A JP 2020523323A JP 2021501150 A5 JP2021501150 A5 JP 2021501150A5
- Authority
- JP
- Japan
- Prior art keywords
- pembrolizumab
- administered
- pharmaceutical composition
- antigen
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960002621 pembrolizumab Drugs 0.000 claims 45
- 239000008194 pharmaceutical composition Substances 0.000 claims 26
- 239000000427 antigen Substances 0.000 claims 21
- 102000036639 antigens Human genes 0.000 claims 21
- 108091007433 antigens Proteins 0.000 claims 21
- 239000012634 fragment Substances 0.000 claims 21
- 206010028980 Neoplasm Diseases 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 7
- 238000011319 anticancer therapy Methods 0.000 claims 6
- 206010073071 hepatocellular carcinoma Diseases 0.000 claims 6
- 231100000844 hepatocellular carcinoma Toxicity 0.000 claims 6
- 238000011272 standard treatment Methods 0.000 claims 6
- 230000009885 systemic effect Effects 0.000 claims 6
- 201000007270 liver cancer Diseases 0.000 claims 4
- 208000014018 liver neoplasm Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 3
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 claims 3
- 208000006265 Renal cell carcinoma Diseases 0.000 claims 3
- 201000008274 breast adenocarcinoma Diseases 0.000 claims 3
- 238000002648 combination therapy Methods 0.000 claims 3
- 201000006972 gastroesophageal adenocarcinoma Diseases 0.000 claims 3
- 201000001441 melanoma Diseases 0.000 claims 3
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 3
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 2
- 208000030808 Clear cell renal carcinoma Diseases 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010073251 clear cell renal cell carcinoma Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 201000011330 nonpapillary renal cell carcinoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762578071P | 2017-10-27 | 2017-10-27 | |
| US62/578,071 | 2017-10-27 | ||
| PCT/US2018/057731 WO2019084418A1 (en) | 2017-10-27 | 2018-10-26 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LIVER CANCER |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021501150A JP2021501150A (ja) | 2021-01-14 |
| JP2021501150A5 true JP2021501150A5 (enExample) | 2021-12-02 |
Family
ID=64453576
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020523323A Pending JP2021501150A (ja) | 2017-10-27 | 2018-10-26 | 肝臓がんを治療するための組成物及び方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20200353022A1 (enExample) |
| EP (1) | EP3700544A1 (enExample) |
| JP (1) | JP2021501150A (enExample) |
| KR (1) | KR20200078483A (enExample) |
| CN (1) | CN111278448A (enExample) |
| AR (1) | AR113805A1 (enExample) |
| AU (1) | AU2018355519A1 (enExample) |
| BR (1) | BR112020007494A2 (enExample) |
| CA (1) | CA3075294A1 (enExample) |
| MX (1) | MX2020003388A (enExample) |
| SG (1) | SG11202002123XA (enExample) |
| TW (1) | TWI817958B (enExample) |
| WO (1) | WO2019084418A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| KR20190139225A (ko) * | 2017-04-28 | 2019-12-17 | 머크 샤프 앤드 돔 코포레이션 | 암 치료제용 생물마커 |
| CN114191547A (zh) * | 2021-12-23 | 2022-03-18 | 中山大学 | 仑伐替尼与pd-1单抗联用在制备抗肝癌药物中的应用 |
| WO2025085538A1 (en) * | 2023-10-17 | 2025-04-24 | Lanier Biotherapeutics, Inc. | Alarmin binding molecules and treatment of cancer |
| WO2025211692A1 (ko) * | 2024-04-02 | 2025-10-09 | (주)에트노바테라퓨틱스 | 암 예방 또는 치료를 위한 병용 투여용 약학 조성물 세트 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| AU2695101A (en) | 2000-01-21 | 2001-07-31 | Biovex Ltd | Virus strains |
| EP2535354B1 (en) | 2007-06-18 | 2017-01-11 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
| KR102031020B1 (ko) | 2011-03-31 | 2019-10-14 | 머크 샤프 앤드 돔 코포레이션 | 인간 프로그램화된 사멸 수용체 pd-1에 대한 항체의 안정한 제제 및 관련된 치료 |
| ES2871910T3 (es) | 2012-08-30 | 2021-11-02 | Amgen Inc | Un método para tratar el melanoma usando un virus de herpes simple y un inhibidor de puntos de control inmunitario |
| EP3169340B1 (en) * | 2014-07-16 | 2020-09-02 | Institut Gustave Roussy | Combination of oncolytic virus with immune checkpoint modulators |
| EP3552615B8 (en) * | 2014-07-16 | 2022-03-02 | Transgene | Oncolytic virus for expression of immune checkpoint modulators |
| BR112017025562A2 (pt) | 2015-05-29 | 2018-08-07 | Merck Sharp & Dohme Corp. | métodos para tratar câncer em um indivíduo e para tratar um indivíduo humano diagnosticado com câncer |
| PL3426271T3 (pl) * | 2016-03-10 | 2025-11-24 | Cg Oncology, Inc. | Sposoby leczenia guzów litych terapią skojarzoną |
| JP2020510624A (ja) * | 2016-12-12 | 2020-04-09 | マルチビア インコーポレイテッド | がんおよび感染性疾患の治療および予防のための、ウイルス遺伝子治療および免疫チェックポイント阻害剤を含む方法および組成物 |
| KR20190139225A (ko) * | 2017-04-28 | 2019-12-17 | 머크 샤프 앤드 돔 코포레이션 | 암 치료제용 생물마커 |
-
2018
- 2018-10-26 AU AU2018355519A patent/AU2018355519A1/en not_active Abandoned
- 2018-10-26 JP JP2020523323A patent/JP2021501150A/ja active Pending
- 2018-10-26 WO PCT/US2018/057731 patent/WO2019084418A1/en not_active Ceased
- 2018-10-26 US US16/759,476 patent/US20200353022A1/en not_active Abandoned
- 2018-10-26 CN CN201880068853.5A patent/CN111278448A/zh active Pending
- 2018-10-26 CA CA3075294A patent/CA3075294A1/en active Pending
- 2018-10-26 AR ARP180103133A patent/AR113805A1/es unknown
- 2018-10-26 MX MX2020003388A patent/MX2020003388A/es unknown
- 2018-10-26 EP EP18807758.0A patent/EP3700544A1/en not_active Withdrawn
- 2018-10-26 KR KR1020207008272A patent/KR20200078483A/ko not_active Ceased
- 2018-10-26 BR BR112020007494-2A patent/BR112020007494A2/pt unknown
- 2018-10-26 SG SG11202002123XA patent/SG11202002123XA/en unknown
- 2018-10-29 TW TW107138162A patent/TWI817958B/zh not_active IP Right Cessation
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021501150A5 (enExample) | ||
| Ferrari et al. | The slippery role of induction chemotherapy in head and neck cancer: myth and reality | |
| JP2019527706A5 (enExample) | ||
| JP2021063120A5 (enExample) | ||
| JP2020515637A5 (enExample) | ||
| RU2019106663A (ru) | Комбинированная терапия рака | |
| JP2016530323A5 (enExample) | ||
| JP2019501204A5 (enExample) | ||
| IL292193B1 (en) | Anti-b7-h1 antibodies for treating tumors | |
| IL276515B1 (en) | PD–L1-specific antibodies and methods of using them | |
| RU2016146993A (ru) | Комбинация антитела к CCR4 и агониста 4-1BB для лечения рака | |
| JP2018070648A5 (enExample) | ||
| RU2017117664A (ru) | Комбинация | |
| JP2015214582A5 (enExample) | ||
| RU2016148645A (ru) | Антитела к в7-н1 и к ctlа-4 для лечения немелкоклеточного рака легкого | |
| JP2017537070A5 (enExample) | ||
| JP2019504105A5 (enExample) | ||
| JP2018521135A5 (enExample) | ||
| JP2017527582A5 (enExample) | ||
| CN112888458A (zh) | Cldn18的抗体和化疗药物的联合治疗 | |
| JP2016528162A5 (enExample) | ||
| JP2017514800A5 (enExample) | ||
| Ding et al. | Immunotherapy-based novel nanoparticles in the treatment of gastrointestinal cancer: trends and challenges | |
| JP2018513155A5 (enExample) | ||
| RU2018101722A (ru) | Днк-вакцина, нацеленная на vegfr-2, для комбинированной терапии |